# US 11,077,174 B2 · Treatment of psychological trauma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,077,174 B2
- Document ID: US11077174B2
- Status: Granted
- Kind: B2
- Application number: 16/665,480
- Filed: 2019-10-28
- Published: 2020-02-27
- Granted: 2021-08-03
- Earliest claimed: 2011-06-13
- Assignees: Allergan, Inc.
- Applicants: Allergan, Inc.
- Inventors: Kenton B. Abel; Andrew M. Blumenfeld
- Web page: https://patentgrep.com/patent/US11077174B2

## CPC

- A61K 38/4893: {Botulinum neurotoxin (3.4.24.69)}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/22: Anxiolytics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present specification discloses methods of treating a psychological trauma in an individual using botulinum toxins and/or a Targeted Exocytosis Modulator, and compositions thereof.

## Claims

### Claim 1

A method of treating or reducing the occurrence of at least one symptom of a psychological trauma disorder in a patient in need thereof, the method comprising the step of administering to the mammal in need thereof a therapeutically effective amount of a composition including a botulinum neurotoxin (BoNT) and/or a Targeted Exocytosis Modulator (TEM), wherein administration of the composition reduces the at least one symptom of the psychological trauma disorder, thereby treating the patient, wherein the at least one symptom of the psychological trauma disorder comprises total or partial amnesia of a traumatic event, flashbacks or nightmares wherein the patient re-experiences the traumatic event, avoidance of stimuli associated with the traumatic event, increased arousal including difficulty falling or staying asleep, anger, hyper-vigilance or combinations thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the BoNT and/or TEM are administered to an Arnold's nerve or a nerve from the recurrent laryngeal nerve complex.

### Claim 3 (depends on 1)

The method of claim 1, wherein the BoNT and/or TEM are administered to: the frontalis at divided among four sites of administration; to the corrugator divided among two sites of administration; to the procerus at one site of administration; to the occipitalis at six sites to eight sites of administration; to the temporalis at eight sites to ten sites of administration; to the trapezius at six sites to ten sites of administration and to the cervical paraspinal muscles at four sites of administration.

### Claim 4 (depends on 1)

The method of claim 1, wherein the BoNT and/or TEM are administered to the glabellar complex.

### Claim 5 (depends on 1)

The method of claim 1, wherein the BoNT is BoNT/A.

### Claim 6 (depends on 1)

The method of claim 1, wherein the psychological trauma disorder is a post-traumatic stress disorder.

### Claim 7 (depends on 1)

The method of claim 1, wherein the psychological trauma disorder is a complex post-traumatic stress disorder.